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Abstract
This article contains the slides and transcript of a talk given by Dan Zaharevitz at the “Visions of a Semantic
Molecular Future” symposium held at the University of Cambridge Department of Chemistry on 2011-01-19. A
recording of the talk is available on the University Computing Service’s Streaming Media Service archive at http://
sms.cam.ac.uk/media/1095515 (unfortunately the first part of the recording was corrupted, so the talk appears to
begin at slide 6, ‘At a critical time’). We believe that Dan’s message comes over extremely well in the textual
transcript and that it would be poorer for serious editing. In addition we have added some explanations and
references of some of the concepts in the slides and text. (Charlotte Bolton; Peter Murray-Rust, University of
Cambridge)
Editorial preface: The following paper is part of a series of publications which arose from a Symposium held at
the Unilever Centre for Molecular Informatics at the University of Cambridge to celebrate the lifetime achievements
of Peter Murray-Rust. One of the motives of Peter’s work was and is a better transport and preservation of data
and information in scientific publications. In both respects the following publication is relevant: it is about public
data and their representation, and the publication represents a non-standard experiment of transporting the
content of the scientific presentation. As you will see, it consists of the original slides used by Dan Zaharevitz in his
talk “Adventures in Public Data” at the Unilever Centre together with a diligent transcript of his speech. The
transcribers have gone through great effort to preserve the original spirit of the talk by preserving colloquial
language as it is used at such occasions. For reasons known to us, the original speaker was unable to submit the
manuscript in a more conventional form. We, the Editors, have discussed in depth whether such a format is
suitable for a scientific journal. We have eventually decided to publish this “as is”. We did this mostly because it
was Peter’s wish that this talk was published in this form and because we agreed with his notion that this format
transmits the message just as well as a formal article as defined by our instructions for authors. We, the Editors,
wish to make clear however that this is an exception that we made because we would like to preserve the
temporal unity and message of this set of publications. Insisting on a formal publication would have meant losing
this historical account as part of the thematic series of papers or disrupting the series. We hope that this will find
the consent of our readership.
Introduction
(Figure 1) This article contains the slides and transcript
of a talk given by Dan Zaharevitz at the “Visions of a
Semantic Molecular Future” symposium held at the Uni-
versity of Cambridge Department of Chemistry on 2011-
01-19. A recording of the talk is available on the Univer-
sity Computing Service’s Streaming Media Service
archive at http://sms.cam.ac.uk/media/1095515 (Endnote
1). We believe that Dan’s message comes over extremely
well in the textual transcript and that it would be poorer
for serious editing. In addition we have added some
explanations and references of some of the concepts in
the slides and text. (Charlotte Bolton; Peter Murray-
Rust, University of Cambridge)
Discussion
(Figure 2) The history of the DTP (Developmental Ther-
apeutics Program) starts in 1955 with a US Congress
specific appropriation to create a national chemotherapy
service centre (Endnote 2). The rationale for this was
that at the time there was no interest in attempting to
develop anti-cancer drugs within the pharma industry. It
was thought not possible to alter the course of the dis-
ease. Compounds were screened for anti-cancer activity.
The primary screen was transplantable mouse models.
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acquiring compounds (Endnote 3), we have registered
more than 550,000 compounds. Roughly half of these
(280,000) were acquired without confidentiality agree-
ment so that data can be publicly made available.
(Figures 3 and 4) What are the sources of data? This
is all on the DTP webpage. For the majority of the his-
tory, the primary screens were L1210 and P388 mouse
leukemias. Some 300,000-400,000 compounds were run
through these models. The screens required significant
Figure 1 Introduction.
Figure 2 DTP History.
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toxicology, which involved lots of animals and lots of
doses, so we needed them to get lots of compound-a
gram or two. This has present day implications-if a
compound was dropped early (e.g. not enough activity,
too much toxicity), a large amount of the compound
was left in our inventory. And this material is now pub-
licly available.
Figure 3 Assays run.
Figure 4 Assays run (continued).
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models were not general enough to pick up solid tumor
agents that people were interested in. So we developed
the human tumor cell-line inhibition screen, known as
NCI-60. We’ve run roughly 100,000 compounds in last
20 years, and this screen is still active. There were a
number of secondary screens dating from the mid90s to
the present: hollow fibre model, where tumor cells are
implanted in a semi-permeable fibre which is implanted
in the mouse. Multiple fibres can be implanted in one
mouse so it’sp o s s i b l et ot e s tm u l t i p l ec e l l - l i n e sp e r
mouse. This gives us a hint of in vivo activity in an effi-
cient and cost-effective assay. We also use human
tumor xenografts in nude mouse: 1500-2000 screens in
the last few years.
Because of the NCI infrastructure for acquiring and
testing interesting compounds, with the sources of com-
pounds and the data, and having the infrastructure
already set up to test large scale compounds and assays
when the AIDS epidemic hit, the screening for anti-HIV
compounds ended up in DTP. In roughly 10 years
1990-2000, DTP assayed roughly 100,000 compounds in
AIDS antiviral screens, looking for survival of cells in
the presence of the virus.
There was also an attempt to create a yeast anti-can-
cer screen. This took yeast with known mutations, gen-
erally in the DNA repair pathway, and treated them
with drugs, looking for toxicity for defined mutations.
Specificity for a particular mutation gives mechanistic
information.
Lastly, with the NCI-60 cell-lines, there has been an
effort to characterise all the cells in these panels in wide
variety of ways. This effort is ongoing. We now have 8-
10 separate measures using microarrays of gene expres-
sion, so there is lots of this available for NCI-60. It’s
very useful to correlate with growth inhibition patterns.
(Figure 5) So all of this created a large amount of data
available to the public. Before 1995 the policy was to
avoid data release if possible. The thinking behind this
was several-fold. It created a lot of extra work. What
data format do you use? The representation was not
well settled, so it’s problematic, even if you had a rea-
sonable electronic representation, how was best to trans-
port it to others? There are physical (tapes) and format
considerations. It’s very difficult to conceive of a way for
widespread distribution of data without an awful lot of
hands-on work. And the extra work doesn’th e l py o ut o
accomplish your ‘real job’. The extra work doesn’tg e t
compounds into the clinic, or give you further informa-
tion about how to do your job. It just sucks up time and
resources.
And it’s of limited value anyway. The data was gener-
ated to make specific decisions, which are already made.
It’s a production environment, you can’t easily examine
alternate decisions. People from outside might ask-why
didn’t you do this? That’s not wrong but in the produc-
tion environment you have to make decisions and move
on. The next couple of thousand compounds are on the
way, you must move forward. Why look at data just to
rehash a decision that couldn’t be re-examined anyway?
(Figure 6) In the mid 1990s there were dramatic
changes. These were driven by the development of the
internet-now distribution is not an issue. You can quite
easily distribute data to hundreds of thousands of people
all over world with virtually no effort. The formats for
chemical structure were more developed, more useful,
embedded in software. It was easier to give people docu-
mentation. HTML made it much easier to give people a
way to collect data with clear and accessible documenta-
tion for that data: what it is, how to use it etc. You
could spend less time on the phone having to explain all
this!
Ken Paull (Endnote 4), former chief of the IT branch,
developed COMPARE, which was looking at the NCI-60
cell-line data, not as individual assay results, is one cell-
line sensitive another not, but at the overall pattern of
activity. If the correlation was high between two com-
pounds, it’s likely to mean that the compounds shared
the mechanism of action. It was a powerful tool to take
ag r o s se m p i r i c a la s s a yt og i v eab i o c h e m i c a li d e ao f
what’s going on. Using assay results as a pattern, to give
an overall finger print of activity is a very powerful tool
compared to looking at these things one at a time.
(Figure 7) And so the very detailed review came about.
It was a year-long review-forty people-it was massive.
And for the purposes here to talk about it I demon-
strated searching and displaying structures and data on
the DTP web pages and showed that you can also run
COMPARE via your web interface. One of the big guns
chased me out of the room where the presentation was
given, was totally excited, he could see that you could
sit in your living room or you could sit in your office
and you could explore all kinds of ideas by just logging
on to a web page, and in 1997 that wasn’te x a c t l yt h e
most widespread notion in the world.
I also presented web stats for how many pages were
accessed. The number of hits weren’t that impressive by
today’s standards but again you’re talking with people
that were used to thinking of contacts as phone, reprint
requests, fax requests, something like that and it was
clear that your ability to respond to requests for outside
information via a website was just enormous compared
to the things you could think about in the 1980s. I also
point out my boss at the time made the specific chal-
lenge to some of the people, the reviewers in the room,
talking about the worth of the developmental therapeu-
tics programme and asked them, you know, big drug
company guys ‘Can you point me to your web page
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the point that there was a difference.
(Figure 8) Lessons learned. I’m gonna call these les-
sons learned. You might say exaggerated extrapolations
from limited knowledge but this is the thing that I take
home from it. So if you think narrowly about your job,
don’t be surprised when the broader community thinks
narrowly about what your job is worth. On the other
Figure 5 Data Release Policies (pre 1995).
Figure 6 Things Change.
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lead to not only better tools for your specific job, you
can be better at what you think you need to do but you
also end up having better integration into the larger
community. And a point that will come back to you
time and time again is, infrastructure development is
critical to enable the ability to take advantage of this
broad thinking. All the good intentions in the world in
Figure 7 At a critical time.
Figure 8 Lessons Learned: I.
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of these things without the infrastructure of the internet.
(Figure 9) So I go now into some details of the chemi-
cal structures we collected (Endnote 5). You can down-
load an SDF file from us and say great I’ll take my
structures and go on. Here is all the stuff I have to deal
with to get it to an SDF file. So in 1955 collecting che-
mical structures meant sort of ink drawings on 3 × 5
cards; that’s the beginnings of our compound collection.
In the 1970s there was this SANSS (Structure and
nomenclature search system) which essentially was a
connection table format. It gave you the atoms and
which atoms were connected and what the bond order
was but it had no coordinate information, no display
information. This I think was partly due to CAS. There
was also the EPA NIH chemical information system that
was coming about here. For about twenty years starting
about 1980 we had what we called the drug information
system. The connection tables were stored in CAS but
you also had a picture. The picture was stored in the
database as HP plotter pen movement commands, so
you can get a picture, you can get a connection table
but you couldn’t put them together at least in any useful
way.
From about 2000 to present we went to a fully inte-
grated relational database, did all those conversions and
right now we have an online submission where we only
accept the structures at the moment in an MDL molfile
format. At least from the beginning we have a computer
representation that comes in. I should point out the
entire time up to the institution of this online request
system, the procedure for asking us to test a compound
was the supplier would send in a picture, would send in
a piece of paper, a graphic so we did not have an elec-
tronic interaction between the requester and our sys-
tems; it was all us doing transfers from some kind of
picture.
(Figure 10) Considerations on what to do; how to get
this into something we can make public. There were
many, many format inter conversions throughout the
fifty years this was going on. One thing to note, and I
think it’s again important, when you see it’s easy to say
here’s a chemical structure, all chemical structures are
alike, they all came from somewhere. If you don’t
understand where they came from you’re not necessarily
gonna understand what the strengths and weaknesses of
various sets are. The first computer representation of
the SANSS was explicitly for sub-structure searching. In
some cases, for example polymers, there was no attempt
to have the connection table represent a full molecule.
The idea was you don’t need to all that information if
you’re not gonna model; it was not for modelling, it was
not for computing properties, it was for doing sub-
structure searching. If you take a polymer, if you had
say a dimer: most of the kind of substructure elements
that you might search for are probably gonna be repre-
sented in the dimer. You can argue trimer or what not,
but you don’t need the whole thing because you’re not
Figure 9 Data Details Chemical structures.
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chain of 200 atoms or something like that. Most sub-
structure searches are more limited so you don’tn e e d
to bother to put the whole molecule in. So what you
end up doing now is having perfectly wonderful SANSS
files, that look perfectly complete, that in fact never ever
had any intention of representing what that molecule
was or what that substance was in a vial.
The display representations also had a fair amount of
what you’d call non-structural features and the one that
drives me up the wall today is a structure that comes
out as a perfectly legal molfile which has one dummy
atom with a label “no structure available”. You know, I
mean, enough said about that, it still drives me up the
wall... But you also have labels so there is a dummy
atom that has a label that actually has something that
you might want to capture. So, composition of the two
parts of the substance: label it as a racemic mixture,
label it as something else so maybe you don’tw a n n a
completely just delete it,’ but at the same time it’s a pol-
lution of the structure with other information in a for-
mat that’s hard to disentangle.
(Figure 11) Structure release. The first one we put on
the NIH page, not a page, just for anonymous FTP. I
think it’s generally called the NCI 127 k. They were
open structures for which there was a CAS number. We
figured the other thing to realise is that a lot of people
say ‘can you give us the chemical names of all these
structures?’ The vast majority of these structures were
not published on, or at least we don’tk n o wt h a tt h e y
were published on: no one ever bothered to name it,
there’s certainly not a trivial name. And so for a lot of
the structures the only identifier we had was the NSC
number and of course back in 1994 nobody knew what
an NSC number was except for a handful of people
interacting with NCI. We didn’t think that was very use-
f u ls ow es u bs e l e c t e das e tw h e r ew ea l s oh a dt h eC A S
numbers. Historical aside: CAS was our input contractor
for about 6 or 8 years about 1975-1983 or something, so
they automatically assigned a CAS number for every-
thing that came in. And so there were CAS numbers:
you figured you might be able to search on that and so
that’sw h e r et h i sg r o u pc a m ef r o m .W h e r ew eg o tt h e
coordinates-it was actually the SANSS connection tables,
they were converted to a SD format and the programme
CORINA [1] from Johann Gasteiger was used to gener-
ate 3D coordinates, so that was the first stage of the
release.
We had our major conversion, a program called
Kekule [2] to look at graphics and try and to chemical
structure. The internal system was finished in 2000 and
so now when we pull from our company database we
are actually pulling MDL format files; so at least it’sa
format that tries to recognise chemicals structure. Right
now we have releases about once a year; we’re hoping
that in the next year we’ll go to a little bit more often
than that. The latest release was a few weeks ago and
265 almost 266 thousand structures. The other thing I’ll
Figure 10 Structure Considerations.
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for a long, long time. A lot of people have pulled them
up and we have PubChem [3] now. A lot of people,
their deposition in the PubChem was basically from a
file that they pulled from us that’s not documented, and
that’sf i n e ,i t ’s legal but there are certainly inconsisten-
cies and differences in all kind of things in this data. If
you go to PubChem and say ‘what’s the structure of
“something-or-other-amycin"?’, and you could look it up
and maybe you find ten versions in PubChem. Ten
depositions for a compound with that name and maybe
you say seven of them have the same actual chemical
structure but there’s these others that are different. Well
I can believe that if seven people think it’s this and only
two people think it’st h a t ,i t ’s probably the seven people
that are correct. But it might be that those seven ver-
sions have a mistake in them that are propagated
because all of them go back to downloading our struc-
tures. So it’s just a heads up that without the back-
ground, without the metadata about where these
structures came from, you can potentially get into pro-
blems or you can potentially be misled.
(Figure 12) So lessons learned number two. It’so n eo f
my pet peeves-a fixed set of fields are a disaster. People
are gonna find a place for the information that they
need to store no matter what, and if you fixed your set
of fields to some gigantic number (’I’m gonna think of
everything possibly people are gonna store’), there’s
always gonna be something you forgot and there’s
always gonna be a huge number of fields in that case
that are never used. So what’st h ep r o b l e m ?J u s ts t i c k
them in as a field that’s never used...but now all your
careful documentation of what that field is for is pol-
luted because people don’t use it like that! Information
will be appended to the expected information in existing
fields, so again you have your case when you are plop-
ping some kind of composition data, some kind of
stereochemical data into a label on a dummy atom in a
structure picture. If that’s the place where you can put
it, people put it there and you’re not gonna stop them.
Use XML!
So we go back to, where did I first meet Peter Mur-
ray-Rust and why am I so high on XML? It’s all because
of Peter. I think the first time I interacted with Peter
was in 1995, maybe one of the earlier attempts at an
internet chemistry poster session, having a chemistry
meeting over the internet and I put in a presentation
about 3D database searching. And Peter started asking
questions basically along the lines of ‘can we get to the
point where we don’t have to do the experiments?’ Well
gee, if you don’t have all the stereochemical information,
this and that, and I said ‘well I don’tt h i n kt h a t ’sar e a l
goal’ and I’m thinking to myself ‘good God man be rea-
sonable’. Of course in the last fifteen years, that’s simply
not a thing you say to Peter! I mean he’s never gonna
be reasonable although he does it in a way that always
pushes us. Thinking about this-I’m not sure 100%
comes through in this talk-that a lot of this stuff really
Figure 11 Structure release.
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tions that are gonna be useful.
Internal database keys should be internal. When you
start to make your internal keys meaningful in the
external world you lose your flexibility and maintaining
really good internal consistency-you should make that
primary. The compound structure is an empirical result;
it is not an identifier and again I don’tk n o ww h e t h e r
PubChem got the terminology right but their distinction
between a compound and the substance I think is extra-
ordinarily important when you talk about chemical
structure data and bioassay data-I’ll give an example of
that
The other thing I’ve learned is identifier equivalencies.
So you have a CAS number, you have a NSC number,
you have this, you have a name, you have all kinds of
stuff. Identifier equivalencies are pivotal too: there are
claims people made-NSC27 is the same as CAS number
blah blah blah. We can use those labels interchangeably-
that’s a claim, and again various people make various
claims and sometimes the claim is wrong and some-
times the claim is misleading. So if you don’t understand
and can’tm a n a g ew h e r et h o s ec l a i m sc o m ef r o ma n d
have access to them you’re gonna eventually run into
problems. I have an aside:
(Figure 13) Think about the difference of writing in a
laboratory notebook ‘50 milligrams of methotrexate’ or
‘50 milligrams of a powder from vial number 123’.T o
give a concrete example, there’s a paper published in
Science about MDMA (3,4-Methylenedioxymethamphe-
tamine, ecstasy). They retracted the paper after they
found out the bottle they had used that was labelled
with MDMA did not actually contain MDMA, but
methamphetamine.
The biggest problem when you make mistakes: it’s
embarrassing, you should double check, but the biggest
problem here was is they couldn’te v e nr e l i a b l ys a y
which experiments were affected by this bottle because
they had done this in their notebooks. They had not
identified the bottle, they just said ‘yeah we used...’ so
chemical structure, chemical name is just a lousy pri-
mary identification field, and you’re really gonna run the
risk of corrupting data and not having full control of
data if you don’t understand this difference.
( F i g u r e1 4 )Ac o u p l eo ft h e s et h i n g si nt h el a s tf e w
slides are labelled community priorities and/or involve-
ment. What I mean by that is these are things I’ve been
thinking of that I think are useful or can potentially be
useful, and obviously in this day and age if you can get
people to help you actually do it that’sf a n t a s t i c ,j u m p
in, let’s go. But for our purposes even expressing a
notion ‘is this a high priority or low priority’, ‘what kind
of thing is useful to us’, that helps us with our limited
resources say ‘well gee a whole lot of people wanna do
this so maybe that is where we put our cut off’ so when
I say this I really would like feedback on any level.
One of the things I have been worried about is how to
make the structure set, the data structure, the chemical
Figure 12 Lessons Learned: II.
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ferent elements in the set so it really does exercise any
kind of chemical software. It’s not just carbon, nitrogen,
oxygen, blah blah blah-there’s I think 300 tin
compounds. We currently use the Chemical Develop-
ment Kit [4] to compare the molecular weight generated
from the molecular formula to the molecular weight
generated from the structure. You go back to this
Figure 13 Aside.
Figure 14 Structure Cleanup (Community priorities/involvement).
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plete molecule or not, only some little bit? The molecu-
lar formula in our data base was always entered
independent of the structure, and so if these two things
match you have a little bit of added confidence that the
structure that came out really does intend to represent
the full structure. If they don’t match then well maybe
you have a problem. A lot of times when they don’t
match, it comes down to this: inconsistencies in formal
charge assignments. A lot of times it is easy to see how
you would clean that up: the molecular formula says
‘dot-CL’, the structure says ‘CL-minus’:O K ,Iu n d e r -
stand that. Some of them are not so clear. Do you try
and use what I mentioned before-do you try and use the
information from these dummy atom labels or do you
just forget about them?
How to document the structures-when and how was
the data extracted, did it come from us, what kind of
algorithms were used to do any kind of clean up or any
kind of comparison. Are there beginning to get ways
that people would like to see structures standardised
more? The most useful way to code this is in the chemi-
cal mark-up language-I’mb e g i n n i n gt ot h i n kt h a tt h e
b e s tw a yt oj u s tt od oi ta n dl e tt h i n g se v o l v e .B u ti f
people have strong opinions on how to represent some
of this and potentially help and correcting or withdraw-
ing bad structures from the community-we had a stu-
dent in the summer crank out about 400 compounds in
a couple of weeks-it might be something people may be
interested in.
(Figure 15) Other data. We have our NCI screening
data-this is growth inhibition in human tumour cell
lines. We have this both as calculated parameters from
af u l ld o s er e s p o n s ec u r v e ,a n da saf u l ld o s er e s p o n s e
curve. I mentioned molecular target data: there’sm i c r o -
array of gene expression in vivo in xenografts, which I
think could be very important; that data is not quite
public yet but it should be soon. We have in vivo survi-
val screens curves from those old mouse model screens,
so if anybody’s interested in developing software or dis-
play tools for looking at survival curves we probably
have something like 200 or 250 thousand survival
curves. That’s publicly available.
I probably don’th a v et i m et ot a l ka b o u tt h i sb u tw e
have about 65 hundred compounds from our inven-
tories now in the molecular library screening deck, so
we have the ability not only to associate NCI-60 data
(let’s say a pattern of activity in the NCI-60 cells) but
then in some cases we have 2 or 3 hundred assays in
the molecular library in PubChem that can be related
to them. We haven’t really started to develop ways to
bring all those things together and try to find ways to
best utilise them. Again, they came from us so again
we have a guarantee that the NCI-60 data and the
molecular library screening data actually all came from
the same sample.
(Figure 16) There are other DTP resources. We have a
compound repository, as I mentioned before. For a good
chunk of our screening, we wanted a couple of grams. If
the molecule was abandoned fairly early on we had a
gram left, so there are about 80,000 compounds for
which I think at least formally we have a gram in our
inventory. We have an online sample request for that.
W eh a v en o tf o rt h em o s tp a r ti d e n t i f i e dt or u na n y
analytics on this, although that’s changing. You can sub-
mit compounds to the screen-we have an online sub-
mission form. In a few months we’ll have web services
and one of the things I’m excited about here is talking
to, say, Alex [Wade]and a few people about ways to use
these web services where you can manage your submis-
sions and accounts in a Word program or something
similar. We also have a COMPARE service server set up
so you can do these calculations. We have put them up
as web services but we haven’t really taken advantage of
that, building alternative interfaces to this and alterna-
tive ways of putting it together with other things. We
haven’t really gone beyond that.
(Figure 17) In terms of what my fantasy-well, hope-
fully it’s not a fantasy (but you know...)-how about an
anti cancer discovery workbench? Sort of a Bioclipse [5]
where you can do structure activity for growth inhibi-
tion, connect to COMPARE to look for compounds
with similar patterns and mechanism. You could order
compounds from DTP, you could connect to COM-
PARE, you can do correlations to COMPARE, not only
look at growth inhibitions versus growth inhibition but
growth inhibition versus molecular target data so you
can prepare growth inhibition to gene expression, see if
a compound has been tested in NCI-60, submit com-
pounds: basically a platform for testing new ways to
analyse structure and data, and also to connect people
that do computational work with synthetic chemists. If
the synthetic chemist is sitting at his bench using this to
submit the compounds to NCI the other tools there
w o u l db ea v a i l a b l et ot h e mt od ow a y so fh o p e f u l l y
prioritising and maximising their chances of getting
good structures submitted.
(Figure 18) And in the last few minutes just talk a lit-
tle bit about sort of philosophy. So the it’s a critical
time for the research community-the funding outlook is
dismal, everybody knows that grant applications success
rates are very low, dissatisfaction with therapeutic pipe-
lines, nobody is happy with the rate and what looks like
the therapeutics. You can say ‘well, more money could
b eab i gh e l p ’, and it could save some things in some
ways but the question is how you justify it.
( F i g u r e1 9 )L e tm eg i v ey o uas p e c i f i cp r o b l e ma n d
this is very dear to my heart because this should be
Zaharevitz Journal of Cheminformatics 2011, 3:34
http://www.jcheminf.com/content/3/1/34
Page 12 of 18exactly what the developmental therapeutics programme
is enabling. There is a paper, published in Nature Medi-
cine in 2006, and it looked for genomic signatures to
guide the use of chemotherapeutics. They started with
our NCI-60 data and our microarray data, fantastic!
They downloaded it and they could do something: they
went beyond it, they got a Nature Medicine paper and it
led to clinical trials. Other questions arose-a letter to
Figure 15 Other Data.
Figure 16 Other DTP resources.
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Page 13 of 18Nature Medicine back and forth, but then a group at
MD Anderson [Cancer Center] couldn’t quite figure out
how they got the results they got. The group at MD
Anderson can download our data as well but couldn’t
quite balance it; the first group would cooperate but
they couldn’t figure things out. It led finally to this
Annals of Applied Statistics paper where the group at
MD Anderson laid out (they called it ‘forensic
Figure 17 Anti-cancer Discovery Workbench (community priority/involvement).
Figure 18 A critical time for the research community .
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Page 14 of 18bioinformatics’), what they tried to do, how they tried to
go about it and the fact that they couldn’tr e a l l yb es u r e
in what was going on. In taking public data, publishing
a paper but not being able to connect the dots so you
know you can... Here’s one particular URL that has a
fairly reasonable overview: resume problems arose, clini-
cal trials halted, a very big mess and it’s a huge problem.
(Figure 20) What you have is an example of what
could be a general problem: it’saw e l lf u n d e dg r o u pi n
a well respected institution, published results in a peer
review journal, favourably reviewed clinical trial plan.
What do you say to the patients when a clinical trial is
halted? ‘O o p s ,s o r r y ,m yb a d ,n op r o b l e m .B yt h ew a y
can you write your congressman and tell them they got
to double our NIH budget?’ There is a real disconnect
there. So what kind of answers can you give? Oh you
know “it was a bad apple"; “this guy is bad"; “he lied so
he probably faked it"; blah blah blah. I don’tt h i n ka n y
of these are acceptable, they are primarily ways to avoid
responsibility by making it a specific problem, but
there’s too many interactions with the entire research
community here to avoid a more general responsibility.
The basic fundamental problem is not any of these (no
it’s not my problem excuses); the problem is the
research community did not demand full accountability,
the parameters for all this review was not something
that was at all able at all to catch this.
(Figure 21) So I call it, Peter says something some-
times about ‘take back our scholarship’,Is a y‘take
responsibility for our scholarship’: insist the data sup-
porting publications be accessible, useable, documen-
ted and complete, and recognise adhering to this
standard. Is what science is, it’s not an add-on, it’sn o t
an extra burden from on high. I claim if you don’t
understand your data well enough to export it, you
don’t understand your data well enough to use it, and
it’s in all scientists’ interests to prevent sloppy scholar-
ship. I don’t think anybody in the research community
benefits from the mess of the genomic signature paper,
whether you were directly a part of it or not. I work in
the molecular library. There is, and again this is indir-
ectly a tribute to Peter, the ethos and the setup of how
data was handled in the molecular library. I strongly
argued for [this] and my arguments were influenced by
Peter’s, but the idea is to make sure that from the
beginning the data was released as soon as it was veri-
fied. But you need to budget for it and you need to
work at it and administratively you need to keep at
these people to do it and it’s been constant: it works
but it doesn’t ‘just happen’.
So in general you know I think you need to think
broadly and carefully about what is promised to the
public in return for their support and you have to make
sure that all these community standards policies and
procedure work toward that goal first the goal of deli-
vering what you are claiming the public benefits from,
and all the other goals are secondary: all the prestige,
the money and all that stuff.
Figure 19 A Specific problem.
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Page 15 of 18(Figure 22) Concrete steps: Open Scholarship, Open
Access. There’sal o to fp e o p l eh e r et h a ta r eg o n n at a l k
more than I about that, but I think that from my perspec-
tive, in addition to a kind of philosophical approach, it’sa
very practical approach where you get better error detec-
tion, potentially better results, better able to connect.
The other thing I’m thinking about is whether can we
actually take that [genomic signature] fiasco and turn it
Figure 20 The General Problem.
Figure 21 Take responsibility for our scholarship.
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Page 16 of 18around and say ‘here’sh o ww ew o u l dd oi tw i t hO p e n
data’, ‘here’s how we would do it in a more documented
way’ and have maybe an Open Genomic Signature
Workbench, so we have in vitro gene expression, we
have growth inhibition data, we’re going to publicly
soon have in vivo gene expression data so we have all
the pieces. NCI has the xenograft testing possibilities so
we have all the pieces for not only generating drug
Figure 22 Concrete Steps.
Figure 23 Conclusion.
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Page 17 of 18expression, drug sensitivity relations but testing them
before you start to go to the clinic and you can do it in
a transparent, documented and reproducible way. We
can show people how it should be done.
(Figure 23) So here’s my email address. All those
things-remember whenever your priorities, interests,
needs: I’m from the government, I’m here to help you.
[Applause]
Question from Egon Willighagen: Are all the charac-
terizations other than the gene expression data of the
NCI-60 publicly available?
Dan Zaharevitz: Yes-we have lots of other different
characterisations so we have metabolomics data we have
enzyme activity measurements but in terms of number
of data points the largest set of data in the molecular
targets set of data is gene expression data just by num-
ber but there’s a lot of other things in there as well
Endnotes
Endnote 1
Unfortunately the first part of the recording was cor-
rupted, so the talk appears to begin at slide 6, ‘At a criti-
cal time’.
Endnote 2
PMR: The NCI research was for many years the out-
standing example of Open, publicly financed research
and data collection. It stemmed from President Nixon’s
“war on cancer” which captured the spirit of the moon-
shots but also shows that biology is tougher than
physics.
Endnote 3
PMR: The systematic testing of public and private com-
pounds was a key strategy for NCI DTP.
Endnote 4
PMR: Ken Paull’s contribution to DTP was dramatic.
The COMPARE program is one of those archetypal
tools which is both very simple and very powerful. It’sa
table “browser” for the DTP data with compounds ==
rows and screens == columns. By tabulating hits com-
pounds can be compared by activity in screens and
screen can be compared by activityof compounds. And
it emphasizes the importance of having lots of data,
carefully aligned, and the tools to manipulate it.
Endnote 5
PMR: In the early years data was “paper”. Chemical
structures were hand drawn.
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